Clinical trials: Atopic Dermatitis (Eczema)
Atopic Dermatitis
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
Atopic dermatitis (AD) is recognized as the most prevalent chronic inflammatory skin disease across all age groups. The introduction of reflectance confocal microscopy (RCM) signifies a substantial leap forward in the…
- Trial name
- NCT07098000
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Atopic Dermatitis
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- UP-TAINED (NCT05139836)
- Where
- 125 sites in Germany
- Volunteers
- 634 people
- Sponsor
- AbbVie
Atopic Dermatitis
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
- Trial name
- NCT03826901
- Testing
- delgocitinib
- Where
- 16 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244230
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 13 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Atopic Dermatitis
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from…
- Trial name
- NCT03047954
- Testing
- Broncho-Vaxom
- Volunteers
- 179 people
- Sponsor
- Vifor Pharma
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Dryness
Glyceryl Eicosapentaenoate Based Topic Products as an Irritant-free Cream and Serum for Hydration of Sensitive Skin
This exploratory study aims to verify the hydrating potential as well as the possible irritant effects of a 14-day hydrating treatment consisting of daily application of serum and cream to the skin of two dry targeted areas.
- Trial name
- COS-PBP-01 (NCT06219213)
- Testing
- Glyceryl Eicosapentaenoate serum, Glyceryl Eicosapentaenoate Cream A, Glyceryl Eicosapentaenoate Cream B
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- SCF Pharma
Atopic Dermatitis, Eczema, Atopic
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).
- Trial name
- NCT05575882
- Testing
- Skin hydration, Barrier function measurement, Potential of hydrogen measurement (pH)
- Where
- 3 sites in Argentina, India and 1 more
- Volunteers
- 100 people
- Sponsor
- NAOS Argentina S.A.
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Itch
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms.
- Trial name
- IL-13 (NCT06503510)
- Testing
- Histamine, Cowhage, bovine adrenal medulla (BAM8-22)
- Where
- 3 sites in Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aalborg University
Atopic Dermatitis, Eczema
The Effects of Emollient Therapy on the Skin Barrier
The goal of this study is to better understand what effect emollients (moisturizers) have on the skin in young children and adults.
- Trial name
- EES (NCT01291940)
- Testing
- Pediatric Moisturizer, Adult Moisturizer
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT05017480
- Testing
- CBP-201
- Where
- 48 sites in China
- Volunteers
- 330 people
- Sponsor
- Connect Biopharm LLC
ATOPIC DERMATITIS
Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting 20% of all babies and children around the world. Diagnosis of atopic dermatitis is clinical and depends on the existence of at least two out of the four…
- Trial name
- NCT01174511
- Testing
- A -1 Cool Cream,Vaselin ointment
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Atopic Dermatitis
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic…
- Trial name
- NCT00231998
- Testing
- Pimecrolimus
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- Novartis
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
- Trial name
- NCT03011892
- Testing
- Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD
- Where
- 52 sites in United States, Canada
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03809663
- Testing
- Tezepelumab
- Where
- 86 sites in United States, Australia and 13 more
- Volunteers
- 251 people
- Sponsor
- Amgen
Nickel; Eczema, Nickel Sensitivity
The Immunological Profile of Nickel Dermatitis
A dose-response study on the immune phenotype of allergic nickel dermatitis on a previously exposed skin area.
- Conditions
- Nickel; Eczema, Nickel Sensitivity, Allergy, Inflammatory Response
- Trial name
- NCT04438330
- Testing
- Nickel sulfate hexahydrate
- Where
- Denmark
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Allergy Research Center, Denmark
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Health Adult Subjects, Moderate-to-Severe Atopic Dermatitis
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07801612
- Testing
- HXN5003
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product…
- Trial name
- NCT02896101
- Testing
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream
- Where
- 27 sites in United States
- Volunteers
- 755 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.